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ACTH resistance is a feature of several human syn-
dromes with known genetic causes, including familial glucocorticoid
deficiency (types 1 and 2) and triple A syndrome. However, many
patients with ACTH resistance lack an identifiable genetic aetiology.




 gene, mutated in a mouse model
of adrenal insufficiency, was sequenced in 25 patients with a clinical

















The primary cohort consisted of 25 unrelated patients,
primarily of European or Middle Eastern descent, with a clinical
diagnosis of either familial glucocorticoid deficiency (FGD) or triple
A syndrome. Patients lacked mutations in other genes known to




 for patients diagnosed with








for patients diagnosed with
familial glucocorticoid deficiency. Thirty-five additional patients
with adrenal disease phenotypes were added to form an expanded

















No disease-causing mutations were found, but several
novel single nucleotide polymorphisms (SNPs) and two putative












 in this collec-
tion of patients with ACTH resistance phenotypes. However, the




 should be more closely examined for
possible links to disease.
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) mutation is a spontaneous
autosomal recessive mouse mutant originally described in 1994 as









mutant animals include growth deficiency, skin
hyperpigmentation, adrenal hypofunction, and reduced survival.




 mutant mice are small relative to body
weight, and they display unique histological characteristics that
include enlarged cortical cells with enlarged nuclei, absence of the
adrenocortical X-zone, and lack of a distinct boundary between
cortical and medullary cells. Previous hormonal studies revealed low
basal corticosterone levels in mutant female mice and elevated ACTH














adrenals did respond to ACTH stimulation, adrenals from wildtype
littermates secreted significantly more corticosterone in response to
ACTH. Aldosterone levels at baseline and in response to ACTH stimu-














 Based on these findings, the




 mutant animals was thought to resemble















a novel telomeric regulator thought to tether the single-strand
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DNA-binding protein POT-1 (protection of telomeres-1) to the TERF1




Primary adrenal insufficiency in humans can be caused by a defect
in adrenocortical growth and/or function. Congenital defects in
adrenocortical function are most often caused by deficiencies in stero-









/– mineralocorticoid deficiency and
compensatory ACTH-driven hyperplasia of the adrenal glands.
Another rare cause of adrenal insufficiency in male subjects is X-linked
adrenoleucodystrophy (OMIM #300100), caused by mutations in





defects in peroxisomal function and accumulation of very long chain
fatty acids, ultimately resulting in destruction of adrenocortical cells.
Defects in adrenal growth are collectively referred to as adrenal
hypoplasia congenita (AHC, OMIM #300200). There are two major





 The cytomegalic form typically presents in early infancy
with adrenal insufficiency, skin hyperpigmentation, and ultimately
delayed puberty due to hypogonadotropic hypogonadism. This form
is characterized histologically by absence of the definitive cortex and









 The miniature adult form is thought to be auto-
somal recessive and is characterized histologically by a thin rim of





mutations in the orphan nuclear receptor SF-1 have been identified




the histological characteristics of the adrenal glands in these indi-
viduals have not been examined.





 mice, also causes adrenal insufficiency in several human
syndromes. Patients with these disorders typically share some char-




mutant phenotype, including low cortisol levels,
significantly elevated ACTH levels, hyperpigmentation, and a poor





individuals often present in the newborn period or during childhood





typical of mineralocorticoid deficiency, is generally not observed in




 As predicted by this pheno-














 only accounted for
25% of the patients with this phenotype, suggesting genetic hetero-
geneity. This group of patients has been referred to collectively as
familial glucocorticoid deficiency type 2 (FGD2, OMIM #607398).




gene, which encodes a novel transmembrane protein that interacts





patients with isolated glucocorticoid deficiency have no identified
mutation in either gene.
ACTH resistance is also a feature of triple A syndrome (OMIM
#231550), a recessive disorder characterized by the triad of adrenal
insufficiency, alacrima, and achalasia. Phenotypic heterogeneity is





ciency is not universally present; it can occur later in the course of




 Furthermore, triple A syndrome patients
with adrenal insufficiency can have isolated glucocorticoid defi-




Additional features that have been reported in triple A syndrome
patients include abnormalities of the central, peripheral, and auto-








) has been iden-




 This protein product,
named ALADIN, localizes to the nuclear pore complex, and it




The exact mechanism by which deficiency in ALADIN causes adrenal
insufficiency has not been determined. Nevertheless, triple A syn-
drome is considered an ACTH resistance syndrome because of the




To date, multiple inherited and sporadic cases have been described













, suggesting that mutations in addi-
tional genes may cause these phenotypes. Because of the phenotypic









 gene for mutations in






For the primary cohort, 25 DNA samples from unrelated patients
with clinical features of FGD or triple A syndrome were obtained
from collaborators. Patients were referred by their paediatric endo-
crinologist, who had made the diagnosis of primary adrenal insuf-
ficiency, or another paediatric subspecialist, who had suspected
triple A syndrome based on cardinal features of alacrima and/or
achalasia. Thirteen were sporadic cases and 12 were familial. Clinical
characteristics are reported in Table 1; genetic studies and family
histories are reported in Table 2. For sporadic patients from non-
consanguineous families, the diagnosis of FGD was made based on
the presence of low cortisol levels, elevated ACTH levels, and lack of
other identifiable causes of adrenal insufficiency, such as adrenal
autoantibodies or adrenoleucodystrophy. Low aldosterone levels
were present in two patients with a clinical diagnosis of FGD (FGD4,
FGD11 in Table 1). In one patient (FGD4), aldosterone and renin
levels normalized after initial treatment for hypoglycaemic shock.




Clinical diagnosis of triple A syndrome was based on the presence
of one or more cardinal features (adrenal insufficiency, alacrima, or
achalasia) in association with neurological symptoms such as
peripheral neuropathy, muscle weakness, mental retardation, or
dysautonomia. Two patients with a clinical diagnosis of triple A syn-
drome did not have evidence of adrenal insufficiency (TA2, TA3 in
Table 1). For the expanded cohort, 35 additional DNA samples from
patients with adrenal disease phenotypes were obtained from
collaborators. These 35 individuals included the 15 patients with
congenital adrenal hypoplasia and IMAGe association reported




 10 additional patients with FGD who were




 mutations (Tables 1, 2), and seven additional
patients with a clinical diagnosis of triple A syndrome in whom




 containing the previously identified single
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 (Tables 1,2); one previously unreported patient with adrenal
insufficiency and hypogonadotropic hypogonadism (Tables 1, 2); and
one previously unreported patient with adrenal hypoplasia (Tables 1, 2).
As a control population, SNP data from the 90 healthy individuals
(180 chromosomes) comprising the Centre d’Etude Polymorphisme




Informed consent was obtained from all patients who participated
in this study in accordance with the established standards of the
referring institutions.






Hormone studies‡ Other symptoms
Cortisol ACTH 
Response 





Primary cohort (n = 25)
TA1 AAAS M  – Low High  –  –  –  –  –
TA2 AAAS M 5 years  –  –  –  –  –  –  –
TA3 AAAS F  –  –  –  –  –  –  –  –
TA4 AAAS F  – Low High  –  –  –  –  –
TA5 AAAS M  – 44 686 No Low  –  – No
TA6 AAAS F 5·2 years 204 High No Low High  –  –
TA7 AAAS F 4 years 66 > 275 No nl nl  –  –
FGD1 FGD F 5 months Low High  –  –  –  –  –
FGD2 FGD M  – Low High  –  –  –  –  –
FGD3 FGD F 4·5 years < 25 461 No nl Yes Yes
FGD4 FGD M 5 years < 25 27·5 No Low High Yes Yes
FGD5 FGD F  – Low High  –  –  –  –  –
FGD6 FGD M  – Low High  –  –  –  –  –
FGD7 FGD F 2 years < 50 High  – nl nl Yes  –
FGD8 FGD F 5 years Low High  –  –  –  –  –
FGD9 FGD M 3 years ND High  – nl  –  –  –
FGD10 FGD M  – Low High  –  –  –  –  –
FGD11 FGD F  – Low High  – Low  –  –  –
FGD12 FGD M 4 years ND High No nl  –  –  –
FGD13 FGD M 6 months 11·1 479  – nl  – Yes  –
FGD14 FGD M  – 41 330 No nl nl Yes Yes
FGD15 FGD M 1 year ND 310 No  –  –  –  –
FGD16 FGD F 3 years < 33 High  – nl  – Yes Yes
FGD17 FGD F 12 years < 10 1459  – nl  –  –  –
FGD18 FGD M 4 months Low High  – nl  –  –  –
Expanded cohort (n = 35)§
EXP1 FGD F Birth ND High No nl  – Yes Yes
EXP2 FGD M  – 200 990  – nl nl Yes Yes
EXP3 FGD M 10 weeks ND 153 No nl nl Yes  –
EXP4 FGD F  – Low High  –  –  –  –  –
EXP5 FGD F Birth 71 110 No  –  –  –  –
EXP6 FGD M 1·5 months ND High No nl  – Yes Yes
EXP7 FGD M  – Low High  –  –  –  –  –
EXP8 FGD M 3 months Low High  –  –  –  –  –
EXP9 FGD F Birth Low > 330  – nl  – Yes Yes
EXP10 FGD M 11 months 50 338 No nl nl No Yes
EXP11 FGD M Birth < 33 > 48 No High High Yes Yes
EXP12 AI/HH M  – Low High  – Low Low  –  –
EXP13 AI F  – Low High  –  –  –  –  –
*Parameters for clinical diagnosis of AAAS and FGD as stated in Materials and Methods. AI, adrenal insufficiency; HH, hypogonadotropic hypogonadism. 
†Specific age given when known. All patients presented during infancy or childhood. ‡Hormone levels given where known. Cortisol levels presented in 
nmol/l (normal morning cortisol, 193–607), ACTH levels presented in pmol/l (normal = 1·1–11·4). For aldosterone and renin, normal (nl) is reported either 
based on laboratory value or on lack of symptoms in patients on glucocorticoid supplementation only. §Expanded cohort also includes 15 patients with 
congenital adrenal hypoplasia and IMAGe association previously reported,16 and seven additional patients with a clinical diagnosis of triple A syndrome 
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Genomic DNA was amplified by polymerase chain reaction (PCR)









 PCR products were separated by electrophoresis and
purified with the QIAGEN Gel Extraction Kit (Qiagen Inc., Valencia,
CA). Samples were sequenced in both directions by the University of
Michigan DNA Sequencing Core, and sequence data were analysed
using Sequencher software, version 4·1·4 (Gene Codes Corp.,
Ann Arbor, MI). All novel SNPs were confirmed in at least two
independent PCR reactions. Genotype data for rs6979 and rs14920
were obtained from http://www.hapmap.org and National
Center for Biotechnology Information (NCBI)’s Single Nucleotide
Polymorphism database (dbSNP).






sporadic ConsanguinityAAAS MRAP ACTHR
Primary cohort (n = 25)
TA1 – ns ns Tunisia Familial Yes
TA2 – ns ns (Arab) Familial Yes
TA3 – ns ns Germany Familial Yes
TA4 – ns ns Turkey Sporadic No
TA5 – ns ns Japan Sporadic No
TA6 – ns ns Germany Sporadic No
TA7 – ns – Israel (Arab) Sporadic No
FGD1 – – – South Africa Sporadic No
FGD2 – – – Netherlands Sporadic No
FGD3 – – – Turkey Familial Yes
FGD4 – – – Turkey Familial Yes
FGD5 – – – Netherlands Familial No
FGD6 – – – Netherlands Sporadic No
FGD7 – – – UK Familial No
FGD8 – – – USA/Arab Familial Yes
FGD9 – – – Netherlands Sporadic Yes
FGD10 – – – Germany/Turkish Sporadic No
FGD11 – – – Germany/Turkish Familial No
FGD12 – – – Germany Sporadic No
FGD13 – – – Bulgarian (Gypsy) Familial No
FGD14 – – – Turkey Sporadic Yes
FGD15 – – – USA Sporadic No
FGD16 – – – USA Familial No
FGD17 ns – – UK/Pakistani Familial Yes
FGD18 ns – – UK/Pakistani Familial Yes
Expanded cohort (n = 35)*
EXP1 – + – Netherlands Sporadic No
EXP2 – + – UK Sporadic No
EXP3 – + – Pakistani/UK Sporadic Yes
EXP4 – + – UK Sporadic No
EXP5 – + – India Familial No
EXP6 – + – Belgium Sporadic No
EXP7 – + – Netherlands Sporadic No
EXP8 – + – Turkey Familial No
EXP9 – + – Anglo-Saxon/US Sporadic No
EXP10 + – – USA Sporadic No
EXP11 – + – Israel (Bedouin) Familial Yes
EXP12 ns ns ns Druze Sporadic Yes
EXP13 ns ns – USA Sporadic No
*Expanded cohort also includes 15 patients with congenital adrenal hypoplasia and IMAGe association previously reported,16 and seven additional patients 
with a clinical diagnosis of triple A syndrome in whom only a portion of the ACD gene was sequenced and for whom limited clinical data are available. –, no 
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 and D’) were performed
using Haploview software, version 3·11 (http://www.broad.mit.edu/
mpg/haploview/index.php). Exonic splicing enhancer (ESE) analysis





Sequence analysis of all 25 unrelated patients in the primary cohort




 gene (Table 3),
two of which were previously represented in dbSNP (SNP3 and





 Of these six SNPs, two were identified in non-
coding regions and four were identified in exons, consisting of two
synonymous SNPs (SNP2 and SNP5) and two nonsynonymous coding
SNPs. Of these, the following relatively conservative substitutions




Ile and SNP3 Val→Ala. None of the non-
synonymous SNPs was in ACD’s predicted POT-1 recruitment
domain3 but SNP3 was in ACD’s predicted TIN2 (TERF1-interacting
nuclear protein 2)-interacting domain.3 Four of the six identified
SNPs were present on more than one chromosome; the remaining
two were singletons (Table 3). Using only nonsingleton SNPs, the
frequency of SNPs in ACD was approximately 1·16 SNPs per kilobase
(kb). The distribution of SNPs appeared to be bimodal with respect
to the structure of the ACD gene; there was an 1868 bp gap extending
from exon 1 to exon 10 in which no polymorphisms were found.
SNP3 had a minor allele frequency (MAF) of 0·48 in our patient
sample (Table 3), which is not significantly different from the MAF
of 0·45 for this allele in the Centre d’Etude Polymorphisme Humain
(CEPH) sample used by the HapMap project.17 The MAFs of SNP4
and SNP6 were both 0·08 (Table 3), corresponding to their presence
on four chromosomes in this sample. Interestingly, the same four
patients who were heterozygous for SNP4 were also heterozygous
for SNP6 (r2 = 1) and also had at least one minor allele of SNP3.
Additionally, SNP5 seemed to be linked with SNP3; all three patients
with the minor allele for SNP5 also had at least one minor allele of
SNP3. Genotypes from the CEPH population confirm this and also
show that in CEPH families, SNP3 and SNP5 are in strong linkage
disequilibrium (D’ = 1). These putative haplotypes involving SNP4-
SNP6-SNP3 and SNP5-SNP3 could not be verified in our sample
because, in the absence of parental DNA, phase could not be deter-
mined. It is for this reason that we label these haplotypes as putative.
Likewise, linkage disequilibrium could not be determined because
the patients were from varied ethnic backgrounds. However, it is
interesting to note that patients who had only one of the two putative
haplotypes had only one minor allele of SNP3, while patients who
had both were homozygous for SNP3’s minor allele. The remaining
SNPs identified in the original sample (SNP1, SNP2) were both pre-
viously unidentified polymorphisms.
To further explore these six polymorphisms an expanded cohort
of 60 individuals, comprising the 25 original patients and 35 addi-
tional subjects with adrenal disease phenotypes, was studied. In an
attempt to confirm the data regarding the putative haplotypes in the
primary cohort, similar analyses were performed in the expanded
cohort. Four additional SNPs were identified, of which three were
novel singleton SNPs and one was previously identified by our group
(SNP7-SNP10, Table 3). As SNP8 is only present in this sample in a
sibling pair, it must also be considered a singleton. As a result, the
number of nonsingleton SNPs per kilobase remained the same in the
expanded cohort at 1·16 SNPs/kb. None of these was predicted to
cause disease. The correlation between SNP4 and SNP6 was reduced
in this sample (r2 = 0·74), but their individual correlations with
SNP3 remained consistent. The SNP5-SNP3 relationship in the
larger sample was also consistent with the primary cohort.
To investigate the possibility of a disease-causing effect, the major
and minor alleles of all 10 SNPs and their surrounding sequences


















1 + G A 1 1 Exon 1 88
2 + C T 1 1 Exon 10 1956
3 rs6979 T C 24 55‡ Exon 11 2522
4 + C A 4 13 Intron 11 2545
5 rs14920 G T 3 6 Exon 12 2675
6 + T A 4 10 3′ UTR§ 2713
7 + G A 0 1 Upstream –399
8 + C T 0 2‡ Exon 10 2112
9 + G A 0 1 Exon 10 2273
10 + G A 0 1 3′ UTR§ 2685
*NCBI’s dbSNP; †numbering of ACD genomic sequence relative to GenBank #AY971883; ‡includes one pair of siblings; §untranslated region.
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were analysed for the presence of transcription factor binding sites.
No significant transcription factor binding sites were abolished when
any of the minor alleles were substituted. Additionally, none of
the SNPs was in conserved or cryptic splice sites or known exonic
splicing enhancer (ESE) sequences, nor were they predicted to create
cryptic splice sites.
Discussion
The acd mutant mouse phenotype is characterized by adrenal hypo-
plasia, with striking changes in the histological characteristics of the
adrenal cortex as well as hormonal evidence of adrenal insufficiency
consisting of gluocorticoid, but not mineralocorticoid, deficiency.
There is considerable overlap between the acd adrenal phenotype
and several different human syndromes featuring adrenal insuffi-
ciency, making it difficult to immediately identify a corresponding
human phenotype with mutations in ACD. We sought to examine
for ACD mutations in patients with adrenal disorders because of the
unique adrenal phenotype observed in acd mice. We previously
reported an analysis of ACD mutations in patients with congenital
adrenal hypoplasia and IMAGe association because this population
of patients shares some features with acd mice, including adrenal
hypoplasia with a cytomegalic histological appearance and the presence
of skeletal defects.16 Given the lack of mutations in this group of
patients and the fact that the hormonal phenotype of acd mice also
resembles aspects of FGD and triple A syndrome, we reasoned that
these patients would be good candidates to examine for ACD mutations.
Twenty-five unrelated patients were sequenced for potential
disease-causing mutations in a 3442 bp region spanning ACD, the
human homolog of the gene that is mutated in the acd mouse model
of adrenal insufficiency. Six polymorphisms were identified in this
primary cohort, two of which are novel. Two SNPs were found on
four chromosomes from unrelated individuals (Table 3), strongly
suggesting that these polymorphisms are indeed SNPs, not rare
isolated mutations. Three additional novel SNPs and one previously
identified SNP were found when the cohort was expanded to include
patients with other adrenal diseases.
Because it is the only nonsynonymous SNP identified in this
sample and because it is in ACD’s predicted TIN2 recruitment
domain, SNP3 seems the most likely candidate for a disease-causing
polymorphism. However, its high minor allele frequency in the 90
healthy CEPH samples does not support a disease-causing role for
this SNP. It is unlikely that the other novel SNPs that we identified
are responsible for causing adrenal insufficiency, given their location
in noncoding, nonconserved regions. Although many diseases
are caused by mutations in regulatory noncoding sequences, these
particular polymorphisms are not predicted to disrupt known
transcription factor binding sites or normal splicing patterns.
Additionally, the fact that patients with adrenal disease from con-
sanguineous families were never homozygous for the minor allele of
any SNP but SNP3 indicates that these SNPs are not disease-causing.
The paucity of nonsingleton SNPs in the region of ACD suggests
that this gene is under constraint, probably indicative of the impor-
tance of ACD’s role in acting at the telomere. The acd mouse muta-
tion, which may be a hypomorphic allele, is embryonic lethal on the
DW/J and C57BL/6 genetic backgrounds.2 It stands to reason then,
that even minor mutations in ACD could result in early lethality,
making them impossible to find in most patient samples. Strong
support for the hypothesis that ACD is under evolutionary constraint
comes from a similar study of genes encoding other telomeric pro-
teins, including POT1 and TIN2, two of ACD’s interacting partners.18
The SNP frequency in the seven genes sequenced in that study
(TERT, POT1, TERF1, TERF2, TNKS, TERF2IP, TINF2) was found
to be significantly lower than frequencies of SNPs in other gene families.
ACD’s SNP frequency of 1·16 SNPs per kb is within the interval of
SNP frequencies previously described for the other telomeric genes
(1·4 ± 0·3 SNPs per kb).18
The possible linkage disequilibrium between SNP4 and SNP6 is
intriguing, given the fact that these are newly identified SNPs in
unrelated families from varying ethnic backgrounds and with vary-
ing adrenal phenotypes. However, confirmation of linkage disequi-
librium would require sequencing a cohort of unaffected individuals
for SNP4 and SNP6 to determine whether this putative haplotype
exists and whether it is associated with adrenal disease.
To date, there are no known human patients with ACD mutations.
Based on the results of the current study and our previous work16 it
is unlikely that mutations in ACD are a major cause of congenital
adrenal hypoplasia, IMAGe syndrome, FGD, and triple A syndrome,
although we cannot exclude the possibility of an ACD mutation in
rare patients with these phenotypes.
Although one hallmark of the acd mouse mutation is adrenal
insufficiency, there is still much work to be done in order to elucidate
the link between telomere biology and adrenal development and
function. Once the molecular links between these areas are identi-
fied, the corresponding genes may be sequenced in patients with
adrenal insufficiency. Any discovered mutations would greatly con-
tribute to the understanding of adrenal function and the develop-
ment of adrenal disease.
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